Chris Peetz

Entrepreneur-in-Residence

Chris is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization.

Chris joined Frazier in May 2017 as founder of Flashlight Therapeutics, a search company focused on identifying and in-licensing assets to treat liver diseases, cancers, and related diseases. He is also the President of Mirum Pharmaceuticals, a Frazier portfolio company.

Chris previously served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics for non-alcoholic steatohepatitis. While at Tobira, Chris led the company's efforts to become a public company, expand its pipeline through partnership and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix.

Chris holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.

Location
Menlo Park
Education

Washington University (B.S.B.A)
Stanford University (M.B.A.)

Year Joined
2017
Contact

Select Investments